Validation study of risk-reduction activities after personalized breast cancer education tool in the WISDOM study.
Journal
NPJ breast cancer
ISSN: 2374-4677
Titre abrégé: NPJ Breast Cancer
Pays: United States
ID NLM: 101674891
Informations de publication
Date de publication:
14 Oct 2024
14 Oct 2024
Historique:
received:
06
04
2023
accepted:
19
07
2024
medline:
14
10
2024
pubmed:
14
10
2024
entrez:
13
10
2024
Statut:
epublish
Résumé
Breast cancer risk reduction strategies have been well-validated, but barriers remain for high-risk individuals to adopt them. We performed a study among participants with high risk of breast cancer to validate whether a virtual breast health decision tool impacted a participant's willingness to start risk-reducing activities, identify barriers to adopting these strategies, and understand if it affects breast cancer anxiety. The study sample was 318 participants in the personalized (investigational) arm of the Women Informed to Screen Depending on Measures of risk (WISDOM) clinical trial. After reviewing the tool, these participants completed a feedback survey. We demonstrated that 15 (4.7%) women were taking endocrine risk reduction, 123 (38.7%) were reducing alcohol intake, and 199 (62.6%) were exercising. In the three-month follow-up survey of 109 respondents, only 8 of 61 (13.1%) women who considered endocrine risk reduction pursued it. In contrast, 11 of 16 (68%) participants who considered alcohol reduction pursued the activity, and 14 of 24 (58%) women who considered exercise followed through. Participants listed fear of side effects as the most common barrier to endocrine risk reduction. We also present further steps to be taken to improve the effectiveness of the Breast Health Decisions tool.
Identifiants
pubmed: 39397069
doi: 10.1038/s41523-024-00681-z
pii: 10.1038/s41523-024-00681-z
doi:
Types de publication
Journal Article
Langues
eng
Pagination
90Subventions
Organisme : Patient-Centered Outcomes Research Institute (PCORI)
ID : PCS-1402-10749
Organisme : U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
ID : R01CA237533
Organisme : U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
ID : K08KCA237829
Investigateurs
Laura Esserman
(L)
Laura van 't Veer
(L)
Robert Hiatt
(R)
Jeff Tice
(J)
Elad Ziv
(E)
Amie Blanco
(A)
Barry Tong
(B)
Katherine Ross
(K)
Allison Fiscalini
(A)
Maren Scheuner-Purcell
(M)
Kimberly Badal
(K)
Kim Rhoads
(K)
Celia Kaplan
(C)
Christina Yau
(C)
Rashna Soonavala
(R)
Katherine Leggat-Barr
(K)
Tomiyuri Lewis
(T)
Patricia Choy
(P)
Steffanie Goodman
(S)
Leah Sabacan
(L)
Kenneth Wimmer
(K)
Kelly Adduci
(K)
Stephanie Flores
(S)
Roxanna Firouzian
(R)
Irene Acerbi
(I)
Arash Naeim
(A)
Neil Wenger
(N)
Carlie Thompson
(C)
Antonia Petruse
(A)
Annette Stanton
(A)
Alexander Borowsky
(A)
Skye Stewart
(S)
Lydia Howell
(L)
Hoda Anton-Culver
(H)
Hannah Lui Park
(HL)
Deborah Goodman
(D)
Lisa Madlensky
(L)
Andrea LaCroix
(A)
Barbara Parker
(B)
Tracy Layton
(T)
Michael Hogarth
(M)
Sheri Hartman
(S)
Diana DeRosa
(D)
John Pierce
(J)
Andrea Kaster
(A)
Jan Wernisch
(J)
Olufunmilayo Olopade
(O)
Rachael Lancaster
(R)
James Esserman
(J)
Martin Eklund
(M)
Yiwey Shieh
(Y)
Karen Sepucha
(K)
Vivian Lee
(V)
Diane Heditsian
(D)
Susie Brain
(S)
Dolores Morehead
(D)
Informations de copyright
© 2024. The Author(s).
Références
Pruthi, S., Heisey, R. & Bevers, T. Personalized assessment and management of women at risk for breast cancer in North America. Women’s Health 11, 213–224 (2015).
pubmed: 25776295
Pruthi, S., Heisey, R. E. & Bevers, T. B. Chemoprevention for breast cancer. Ann. Surg. Oncol. 22, 3230–3235 (2015).
doi: 10.1245/s10434-015-4715-9
pubmed: 26202562
pmcid: 4550636
Gilman, E. A., Pruthi, S., Hofstatter, E. W. & Mussallem, D. M. Preventing breast cancer through identification and pharmacologic management of high-risk patients. Mayo Clin. Proc. 96, 1033–1040 (2021).
doi: 10.1016/j.mayocp.2021.01.028
pubmed: 33814072
Rahman, R. L. & Pruthi, S. Chemoprevention of breast cancer: the paradox of evidence versus advocacy inaction. Cancers 4, 1146–1160 (2012).
doi: 10.3390/cancers4041146
pmcid: 3712728
Brewster, Abenaa Chemoprevention for breast cancer: overcoming barriers to treatment | American Society of Clinical Oncology Educational Book. Am. Soc. Clin. Oncol. Educ. Book. 32, 85–90 (2012).
doi: 10.14694/EdBook_AM.2012.32.152
Land, S. R. et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention. The NSABP study of tamoxifen and raloxifene (STAR) P-2 Trial. JAMA 295, 2742–2751 (2006).
doi: 10.1001/jama.295.23.joc60075
pubmed: 16754728
Yi, H. et al. Barriers and facilitators to patient-provider communication when discussing breast cancer risk to aid in the development of decision support tools. AMIA Annu. Symp. Proc. 2015, 1352–1360 (2015).
pubmed: 26958276
pmcid: 4765687
Hum, S., Wu, M., Pruthi, S. & Heisey, R. Physician and patient barriers to breast cancer preventive therapy. Curr. Breast Cancer Rep. 8, 158–164 (2016).
doi: 10.1007/s12609-016-0216-5
pubmed: 27617055
pmcid: 4995234
Heisey, R., Pimlott, N., Clemons, M., Cummings, S. & Drummond, N. Women’s views on chemoprevention of breast cancer: qualitative study. Can. Fam. Phys. Med. Fam. Can. 52, 624–625 (2006).
Stacey D. et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst. Rev. https://doi.org/10.1002/14651858.CD001431.pub4 . (2014).
Keane, H. et al. Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial. Npj Breast Cancer 7, 1–9 (2021).
doi: 10.1038/s41523-021-00288-8
Esserman, L. J. The WISDOM Study: breaking the deadlock in the breast cancer screening debate. Npj Breast Cancer 3, 1–7 (2017).
doi: 10.1038/s41523-017-0035-5
Sabatino, S. A., McCarthy, E. P., Phillips, R. S. & Burns, R. B. Breast cancer risk assessment and management in primary care: provider attitudes, practices, and barriers. Cancer Detect. Prev. 31, 375–383 (2007).
doi: 10.1016/j.cdp.2007.08.003
pubmed: 18037249
Corbelli, J. et al. Use of the gail model and breast cancer preventive therapy among three primary care specialties. J. Women’s Health 23, 746–752 (2014).
doi: 10.1089/jwh.2014.4742
Samimi, G. et al. Assessment of and interventions for women at high risk for breast or ovarian cancer: a survey of primary care physicians. Cancer Prev. Res. 14, 205–214 (2021).
doi: 10.1158/1940-6207.CAPR-20-0407
D’Agostino, R. B. & Vasan, R. S. General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation 17, 6 (2008).
Ebell, M.H. & Grad, R. Top 20 research studies of 2021 for primary care physicians AAFP. Accessed January 6. https://www.aafp.org/pubs/afp/issues/2022/0700/top-poems-2021.html . (2023).
Gibbons, A. & Groarke, A. Can risk and illness perceptions predict breast cancer worry in healthy women? J. Health Psychol. 21, 2052–2062 (2016).
doi: 10.1177/1359105315570984
pubmed: 25712488
Grimm, L. J. et al. Frequency of breast cancer thoughts and lifetime risk estimates: a multi-institutional survey of women undergoing screening mammography. J. Am. Coll. Radiol. 16, 1393–1400 (2019).
doi: 10.1016/j.jacr.2018.12.031
pubmed: 30826236
Seven, M., Bağcivan, G., Akyuz, A. & Bölükbaş, F. Women with family history of breast cancer: how much are they aware of their risk? J. Cancer Educ. 33, 915–921 (2018).
doi: 10.1007/s13187-017-1226-3
pubmed: 28474221
Xie, Z. et al. Risk estimation, anxiety, and breast cancer worry in women at risk for breast cancer: a single-arm trial of personalized risk communication. Psychooncology 28, 2226–2232 (2019).
doi: 10.1002/pon.5211
pubmed: 31461546
pmcid: 6858926
Hartley, C. A. & Phelps, E. A. Anxiety and decision-making. Biol. Psychiatry 72, 113–118 (2012).
doi: 10.1016/j.biopsych.2011.12.027
pubmed: 22325982
Beckers, T. & Craske, M. G. Avoidance and decision making in anxiety: an introduction to the special issue. Behav. Res. Ther. 96, 1–2 (2017).
doi: 10.1016/j.brat.2017.05.009
pubmed: 28545650
pmcid: 5551966
van Erkelens, A. et al. Online self-test identifies women at high familial breast cancer risk in population-based breast cancer screening without inducing anxiety or distress. Eur. J. Cancer 78, 45–52 (2017).
doi: 10.1016/j.ejca.2017.03.014
pubmed: 28412588
French, D. P., Howell, A. & Evans, D. G. Psychosocial issues of a population approach to high genetic risk identification: behavioural, emotional and informed choice issues. Breast 37, 148–153 (2018).
doi: 10.1016/j.breast.2017.11.008
pubmed: 29161653
Dietz, J. R. et al. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium. Breast Cancer Res. Treat. 181, 487–497 (2020).
doi: 10.1007/s10549-020-05644-z
pubmed: 32333293
pmcid: 7181102
Sutherland K. et al. Impact of COVID-19 on healthcare activity in NSW, Australia. Public Health Res. Pract. 30:3042030 (2020).
Wang, T., Che, M. & Esserman, L. BHD tool validation study. OSF https://doi.org/10.17605/OSF.IO/YJ782 (2023).
Wang, T. Breast health decisions tool validation study code. Zenodo. https://doi.org/10.5281/zenodo.8374402 . (2023).